EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis

Min Liu, Taixue Zhao, Jinyang Zhang, Bing Bu, Ruyi Zhang, Xueshan Xia, Jiawei Geng iD

Reviews in Medical Virology · 2024

DOI: 10.1002/rmv.2570 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Reviews in Medical Virology, 2024. Verfasst von Min Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University o…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Xing Dian Ying Cai Support Plan of Yunnan Province, Yunnan Zhang Wenhong export workstation, Kunming University of Science of Technology & the First People's Hospital of Yunnan Province Joint Special Project on Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The question of whether patients in the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection should undergo antiviral therapy and determine the optimal regimen remains unclear. A comprehensive search of PubMed, Embase, MEDLINE, Cochrane Library, and Wanfang Data from inception to 5 December 2023, was conducted. Studies reporting on key outcomes such as HBV DNA undetectability, HBeAg loss or seroconversion, HBsAg loss or seroconversion, and hepatocellular carcinoma (HCC) incidence in patients in the IT phase of chronic HBV infection were included. In total, 23 studies were incorporated. Approximately 4% of patients in the IT phase achieved spontaneous HBeAg loss over 48 weeks of follow‐up. Antiviral therapy demonstrated a favourable impact on HBV DNA negative conversion (Children: risk ratios [RR] = 6.83, 95% CI: 2.90–16.05; Adults: RR = 25.84, 95% CI: 6.47–103.31) and HBsAg loss rates (Children: RR = 9.49, 95% CI: 1.74–51.76; Adults: RR = 7.35, 95% CI: 1.41–38.27) for patients in the IT phase. Subgroup analysis revealed that in adult patients in the IT phase, interferon plus nucleos(t)ide analogues (NA)‐treated patients exhibited a higher pooled rate of HBsAg loss or seroconversion than those treated with NA monotherapy (9% vs. 0%). Additionally, the pooled annual HCC incidence for patients in the IT phase was 3.03 cases per 1000 person‐years (95% CI: 0.99–5.88). Adult patients in the IT phase had a significantly lower HCC incidence risk than HBeAg‐positive indeterminate phase patients (RR = 0.46, 95% CI: 0.32–0.66), with no significant differences observed between IT and immune‐active phases. Presently, there is insufficient evidence solely based on reducing the risk of HCC incidence, to recommend treating patients in the IT phase of chronic HBV infection. However, both adult and paediatric patients in the IT phase responded well to antiviral therapy, showing favourable rates of HBsAg loss or seroconversion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsAntiviral AgentsHepatitis B e AntigensHumansHepatitis B virusIncidenceHepatitis B Surface AntigensDNA, ViralImmune ToleranceTreatment OutcomeSeroconversion

Stichwörter der Autor:innen

adultchildrenchronic hepatitis Bimmune tolerancemeta‐analysis

Substanzen

Antiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensDNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Disease and Hepatic Disease, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
  • Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China.
  • Medical School of Kunming University of Science and Technology, Kunming, Yunnan, China.
  • Kunming Medical University, Kunming, Yunnan, China.

ORCID-Profile: Jiawei Geng

Förderung

  • Xing Dian Ying Cai Support Plan of Yunnan Province
  • Yunnan Zhang Wenhong export workstation
  • Kunming University of Science of Technology & the First People's Hospital of Yunnan Province Joint Special Project on Medical Research
  • Yunnan Major Scientific and Technological Projects

Zitieren

APA

Liu, M., Zhao, T., Zhang, J., Bu, B., Zhang, R., Xia, X., & Geng, J. (2024). Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis. Reviews in Medical Virology. https://doi.org/10.1002/rmv.2570

Vancouver

Liu M, Zhao T, Zhang J, Bu B, Zhang R, Xia X, et al. Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis. Reviews in Medical Virology. 2024. doi:10.1002/rmv.2570

BibTeX
@article{Liu2024,
  author = {Liu, Min and Zhao, Taixue and Zhang, Jinyang and Bu, Bing and Zhang, Ruyi and Xia, Xueshan and Geng, Jiawei},
  title = {Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis},
  journal = {Reviews in Medical Virology},
  year = {2024},
  doi = {10.1002/rmv.2570}
}
Kostenlos starten →